Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers. / Johannesen, Caroline Klint; Martin, Gry St; Lendorf, Maria Elisabeth; Garred, Peter; Fyfe, Alexander; Paton, Robert S.; Thompson, Craig; Molsted, Stig; Kann, Caroline Elisabeth; Jensen, Claus Antonio; Hansen, Cecilie Bo; Løkkegaard, Ellen; Christensen, Thomas Broe; Simmonds, Peter; Fischer, Thea K.
I: Danish Medical Journal, Bind 69, Nr. 5, A11210843, 2022.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Prevalence and duration of anti-SARS-CoV-2 antibodies in healthcare workers
AU - Johannesen, Caroline Klint
AU - Martin, Gry St
AU - Lendorf, Maria Elisabeth
AU - Garred, Peter
AU - Fyfe, Alexander
AU - Paton, Robert S.
AU - Thompson, Craig
AU - Molsted, Stig
AU - Kann, Caroline Elisabeth
AU - Jensen, Claus Antonio
AU - Hansen, Cecilie Bo
AU - Løkkegaard, Ellen
AU - Christensen, Thomas Broe
AU - Simmonds, Peter
AU - Fischer, Thea K.
N1 - Publisher Copyright: © 2022, Almindelige Danske Laegeforening. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.
AB - Introduction. Knowledge of the seroprevalence and duration of antibodies against SARS-CoV-2 was needed in the early phases of the COVID-19 pandemic and is still necessary for policy makers and healthcare professionals. This information allows us to better understand the risk of reinfection in previously infected individuals. Methods. We investigated the prevalence and duration of detectable antibodies against SARS-CoV-2 in sequentially collected samples from 379 healthcare professionals. Results. SARS-CoV-2 seroprevalence at inclusion was 5.3% (95% confidence interval (CI): 3.3-8.0%) and 25% of seropositive participants reverted during follow-up. At the end of follow-up, the calculated probability of having detectable antibodies among former seropositive participants was 72.2% (95% CI: 54.2-96.2%). Conclusion. Antibodies against SARS-CoV-2 were detectable in a subset of infected individuals for a minimum of 39 weeks.
M3 - Journal article
C2 - 35485785
AN - SCOPUS:85129100901
VL - 69
JO - Danish Medical Journal
JF - Danish Medical Journal
SN - 2245-1919
IS - 5
M1 - A11210843
ER -
ID: 314061343